QT Imaging Holdings reported second‑quarter Revenue of $7.4 million, a 103 % increase from $3.7 million a year earlier, driven by 15 scanner shipments. The surge lifts Earnings potential but widening losses and a higher expense base warn investors of near‑term profitability challenges.
Key Highlights
- Second‑quarter revenue hit $7.4 million, up 103 % YoY, after shipping 15 Breast Acoustic CT scanners.
- The company raised $10.0 million in an underwritten public offering and extended its senior secured term Loan to March 31 2029.
- Gross Margin fell to 41 % from 50 % YoY while operating loss widened to $1.9 million, reflecting higher expenses and a $8.3 million non‑cash Debt extinguishment loss.
QT Imaging Holdings, Inc. reported second‑quarter revenue of $7.4 million, representing a 103 % increase over the $3.7 million recorded a year earlier. The surge was driven by the shipment of fifteen Breast Acoustic CT scanners during the quarter, adding to a cumulative total of twenty‑eight units delivered in the first six months of the year. This acceleration in hardware deployments signals a tangible widening of the company’s install base and suggests that customers are responding positively to the radiation‑free breast‑health solution.
Correspondingly, first‑half revenue rose to $14.0 million, an uplift of 116 % compared with the same period last year, reinforcing the narrative of rapid market penetration. The parallel rise in both quarterly and half‑year toplines underscores the effectiveness of QT Imaging’s go‑
Revenue Surge Details
The $7.4 million second‑quarter Top Line more than doubled year‑over‑year, reflecting strong Demand for QT Imaging’s radiation‑free breast health platform. Fifteen scanners left the factory in the quarter, raising the total shipped to 28 for the first six months, a clear indicator of expanding install base. First‑half revenue of $14.0 million, up 116 % from the prior year, validates the company’s aggressive go‑to‑market strategy.
Reaffirming a $39 million full‑year target reinforces management’s belief that the sales momentum will persist despite competitive pressures. Investors will watch whether the current trajectory can sustain the guidance, as any shortfall could pressure valuation.
Capital and Cost Structure
A $10.0 million underwritten public offering bolstered the balance sheet, providing Liquidity for scale‑up activities and mitigating financing risk. The senior secured term loan was extended to March 31 2029, lengthening debt Maturity and easing near‑term cash‑flow constraints. Operating expenses rose to $4.9 million from $2.9 million a year ago, driven by higher staffing costs, professional services, and Marketing spend, widening the operating loss to $1.9 million versus $1.0 million previously.
Gross margin contracted to 41 % from 50 %, reflecting a higher weighted‑average inventory cost. Adjusted EBITDA remained negative at $1.2 million, or $0.08 per share, highlighting ongoing profitability challenges. The Capital infusion and extended loan term improve financial flexibility, but the widening loss profile raises concerns about cash‑burn rate.
Operational Milestones
QT Imaging secured regulatory clearances in Israel and Saudi Arabia, expanding its geographic footprint and opening new revenue channels. A routine FDA inspection concluded with zero Form 483 observations, evidencing strong quality controls. Leadership additions, including a Chief Science Officer and a Senior Medical Advisor, enhance the firm’s clinical and innovation capacity.
The move to a 22,000‑square‑foot headquarters and Manufacturing hub triples operational space while cutting Lease costs per square foot by roughly 55 %, positioning the firm for scalable production. These advances lay a solid foundation for broader adoption of the Breast Acoustic CT platform, yet the ability to translate regulatory wins into sustained sales remains to be proven.
Outlook and Catalysts
Management reaffirmed the approximately $39 million full‑year revenue target, betting on continued scanner deployments and expanding direct sales teams. The next quarterly earnings release will test whether the sales pipeline can convert into the projected top‑line growth and narrow the widening loss margin. Investor focus will turn to the company’s ability to Leverage its new manufacturing capacity and regulatory approvals while managing operating expenses.
The upcoming results will be a decisive barometer for the firm’s scaling strategy and its capacity to deliver Shareholder value.






Please wait processing your request...